A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer

MLA

Minal A. Barve, et al. “A Phase II Trial Combining Tumor-Targeting TP53 Gene Therapy with Gemcitabine/Nab-Paclitaxel as a Second-Line Treatment for Metastatic Pancreatic Cancer.” Journal of Clinical Oncology, vol. 39, May 2021, p. 4139. EBSCOhost, https://doi.org/10.1200/jco.2021.39.15_suppl.4139.

APA

Minal A. Barve, Esther H. Chang, Ming-Shiang Wu, Shih-Hung Yang, James Strauss, Wei-Chih Liao, Jana Adams, Robert Nunan, Kathleen F. Pirollo, Chris P. Leung, & Joe B. Harford. (2021). A phase II trial combining tumor-targeting TP53 gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer. Journal of Clinical Oncology, 39, 4139. https://doi.org/10.1200/jco.2021.39.15_suppl.4139

Chicago

Minal A. Barve, Esther H. Chang, Ming-Shiang Wu, Shih-Hung Yang, James Strauss, Wei-Chih Liao, Jana Adams, et al. 2021. “A Phase II Trial Combining Tumor-Targeting TP53 Gene Therapy with Gemcitabine/Nab-Paclitaxel as a Second-Line Treatment for Metastatic Pancreatic Cancer.” Journal of Clinical Oncology 39 (May): 4139. doi:10.1200/jco.2021.39.15_suppl.4139.